Moleac
From Wikipedia, the free encyclopedia
Moleac is a biopharmaceutical company based in Singapore
Moleac is headquartered in Singapore. Its operations and research are located in Biopolis, a world-class purpose built complex for biomedical sciences research www.biopolis.com
Moleac brings together Asian and Western medicines by identifying promising medicine discovered in China and developing them into Western mainstream medicine. Conversely Moleac develops and markets in Asia innovative technologies and medical products that are in-licensed from Europe.
Contents |
[edit] Products and Pipeline
Moleac's first product, NeuroAid is focused on brain stroke recovery and is derived from Traditional Chinese Medicine. It has gained market approval in two countries in 2006 and a clinical trial was started in October 2007 with 1100 patients.
In march 2008, Moleac launched in the US market, Neuroaid10, a simplified version of Neuroaid which contains all the major herbal ingredients of Neuroaid and is marketed as a dietary supplement to help support Neurological functions.
Moleac's pipeline includes a smoking cessation therapy planned to be marketing in 2008, as well as several drugs and devices in various stages of development to address unmet medical needs.
[edit] Key Partnerships
Partnerships have been entered with the following institutions:
Shitian Pharmaceuticals Shitian has developed a portfolio of drugs and natural products derived mainly from advanced research carried out in the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. Shitian Pharmaceuticals
Peking University School of Oncology The School of Oncology of Peking University (Beijing) is a hospital and research center in China. Moleac has partnered with Peking University School of Oncology to develop clinically a phyto-oestrogen free treatment for hot flashes following natural, drug induced or surgical induced menopause.
CHIMES Society CHIMES Society is an international academic collaboration whose objective is to establish new stroke treatments. CHIMES is a Singaporean non profit society founded by a group of Key Opinion Leaders in stroke, South-East Asia regional experts and clinicians interested in implementing a research project on Traditional Chinese Medicine Efficacy on Stroke recovery. In October 2007, CHIMES Society initiated a 1100 patient clinical trial aimed at measuring the efficacy of NeuroAid in reducing neurological deficit and improving functional outcome in patients with cerebral infarction. This trial is currently enrolling and details are available at the NHI www.ClinicalTrial.gov database under the identifier NCT00554723.
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine(Tianjin Medical University) First Teaching Hospital of Tianjin University of TCM is the largest TCM hospital of China. It was first established in 1954.
[edit] Board of Directors
Marc Vasseur, Chairman of the Board In 1989, Marc co-founded Genset and has been board member, Chief Biology Officer and General Manager of the company until 2000. During this period, Marc Vasseur founded Genset's subsidiaries in Kyoto (Genset KK) and Singapore (now Proligo). Marc left Genset from July 2000 to March 2002. During this period, he was involved in the launch of a number of biotechnology companies spinning off from the Pasteur Institute.
He came back to Genset in March 2002 and was appointed CEO and Chairman. He has managed the acquisition of Genset by Serono through a tender offer. Marc is now the CEO and Chairman of Serono France Holding.
Marc has also served as a Director of several other biotechnology companies, and actively participates and has participated in advisory boards of several investment funds. Before launching Genset, Marc had been a director of biological research at L'Oreal, after working 10 years at the Pasteur Institute.
Marc Vasseur is also a former Professor of Virology at the University of Paris, and has taught in many universities world-wide, including Zhonshan University in Guangzhou Marc Vasseur has also sat on a number of boards, ranging from research institutions such as CNRS to various advisory committees at the Ministry of Research and Industry in France. He is also Chairman and CEO of Serono Holding France.
Marc co-founded Moleac, he contributes considerable experience and knowledge in research management, clinical and regulatory strategies Intellectual Property management and business development.
David Picard, Chief Executive Officer David co-founded Moleac and has served as CEO since. Over the past years David has structured the team, identified key scientific, clinical, and business partners in China, Singapore and Europe, and implemented the business agreements.
Prior to founding Moleac, David has spent ten years at The Boston Consulting Group ("BCG") where he was a member of the worldwide Health Care Practice Area. He has worked both in Europe and in Asia. He has extensive experience in working in Greater China and in Korea.
David graduated from the two top engineering schools in France, Ecole Polytechnique and Ecole Nationale Supérieure des Mines de Paris, where he majored in mathematics and economics. David also holds a French degree ("DESS") in business law.
Bounmy Rattanavan, Non-Executive Director Bounmy, a French national of Chinese origin, co-founded Tang Frères with his brother. Tang Frères started twenty five years ago as the leading Asian food import/export business in France.
Through Tang Frères, Bounmy has established an influential network in Europe and in China which has positioned him to be a the partner of choice to several multinationals wanting to build and expand business in China. Bounmy has developed many businesses between Europe and China and is active in industry such as biotechnology, enzymes, retailing, media, food, ...
Bounmy co-founded Moleac and contributes his strong entrepreneurial experience in Europe and in China, and his valuable knowledge of China scientific academies and regulatory system.
Christophe Polini, Non-Executive Director Christophe Polini is the Company General Secretary of Tang Frères, where he has worked for more than a decade, first as legal director and since 2000 as its General Secretary. Christophe holds a Master in Laws and has worked in law firms and as the legal director of Afflelou.
Christophe brings to Moleac a strong experience of structuring and managing partnerships in China.
[edit] Scientific Advisory Board
Daniel Cohen, Chairman of Scientific Advisory Board Professor Daniel Cohen, 53, is a leading expert and pioneer in the field of genetics. Daniel Cohen is known as the founder of modern genetics, and the "Henry Ford" of the genome, since he was the first to industrialise and upscale the discovery process.
Daniel Cohen is the co-founder of CEPH, Centre d'Etude du Polymorphisme Humain, a non for profit organization devoted to genetic diseases. In the early 1980's, he has been the first scientist to envision, launch and conduct large scale analysis of the human genome, producing the first physical maps of the genome. Joining Genset with all his team in 1995, Daniel Cohen has directed number of R&D partnerships with big pharmas, delivering new data, targets and potential therapeutics in various fields, ranging from cancer to psychiatric diseases.
Professor Daniel Cohen was the first to introduce and develop the concept of pharmacogenomics, which led to the first agreement of its kind in this field between Genset and Abbott Laboratories in 1997.
Professor Daniel Cohen serves or has served as a scientific advisor to several biotech companies. He is also a recipient of numerous awards, including the Daniel Bauperthuy Prize from the French Academy of Sciences, and the American Academy of Achievement's Golden Plate Award. He is also Honoured Doctor from the University of Xian and from the University of Shanghai.
Professor Cohen has authored more than 100 scientific publications, in leading scientific journals. He is chevalier of French Legion of Honor.
Daniel Cohen co-founded Moleac with David Picard, Marc Vasseur and Bounmy Rattanavan. Daniel contributes his considerable expertise in genetic research and drug discovery and development.
